<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ge.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">
		
		//delay = 500;
		ANIMATION = [

                 mask('.QD'),
				 fade('.BID-labels, .QD-labels')
				//'h2',
				//stagger('.element')
		   ];
		
	</script>

</head>

<body class="slide-3">

<div id="content">
<div class="collage"></div>

<header>
Study 730: Viral load suppression was similar <br>between QD and BID arms

</header>

<div class="logo"></div>

<section>

<article>
	<div class="chartwrap">
    	<div class="chartbk"></div>
        <div class="title">Proportion of patients with HIV-1 RNA &lt;50 copies/mL<br>through week 48 (ITT, NC=F and OT analysis)<sup>6</sup></div>
    	<div class="QD" style="overflow:hidden;"><div class="BID"></div></div>
        
        <div class="QD-labels"></div>
        <div class="BID-labels"></div>
    
    
    </div>
    <div class="chartdisc">ITT, intent-to-treat; OT, on-treatment; NC=F, <br>non-completer equals failure. </div>

</article>

<aside>

<p><strong>Subject Disposition</strong></p>
<p class="bullet">In the QD group, 4.8% of patients <br>discontinued treatment due to <br>adverse events, 0.6% due to death, 0.6% due to virologic failure, 12% for other reasons*; 85.3% of patients <br>completed the study.</p>
<p class="bullet">In the BID group, 3% of patients <br>discontinued treatment due to adverse events, 0.3% due to death, 1.5% due to virologic failure, 14% for other reasons*; 83.4% of patients completed the study.</p>
<p class="bullet">Virologic failure through week 48: 10%<br>in the QD group and 8% in the BID group. Virologic failure includes <br>confirmed viral rebound and failure to achieve confirmed HIV RNA &lt;50 copies/mL through week 48.</p>
<p class="smtext">*Other reasons include lost to follow-up, non-adherence, withdrawal of consent, and other. Subjects/investigators may have provided more than one reason for discontinuation.</p>
</aside>


</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('ge-03-popup-01','Study Design','<table width=\'670px\'><tr align=\'center\'><td class=\'reference\'>730 Study Design<sup>6</sup></td></tr></table>','90','625','10','0','670','545','1','0','1','0'));">Study Design</button>
    <button onclick="makecall('PopupWithHeader',Array('ge-03-popup-02','Baseline Values','<table width=\'750px\'><tr align=\'center\'><td class=\'reference\'>730 Baseline Values<sup>6</sup></td></tr></table>','230','625','10','0','750','545','1','0','1','0'));">Baseline Values</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>